<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03801707</url>
  </required_header>
  <id_info>
    <org_study_id>2018H0499</org_study_id>
    <nct_id>NCT03801707</nct_id>
  </id_info>
  <brief_title>Utilization of Hepatitis C Positive Kidneys in Negative Recipients</brief_title>
  <acronym>USE-Hep C</acronym>
  <official_title>An Open Label, Prospective, Interventional, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative Recipient Using Sofosbuvir/Velpatasvir as a Treatment for Post-Transplant HCV Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV)
      infected donors into recipients without HCV infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label, prospective, interventional, proof of concept study to evaluate
      the feasibility and safety of kidney transplant from HCV positive donors into HCV negative
      recipients using Sofosbuvir/Velpatasvir as a treatment for post-transplant HCV transmission
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with undetectable HCV PCR at 12 weeks after completion of HCV treatment with Sofosbuvir/Velpatasvir</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of adverse events related to Sofosbuvir/Velpatasvir drug therapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>eGFR at 6 and 12 months post-transplant</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's survival at 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Kidney Transplant</condition>
  <condition>Hepatitis C</condition>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir/Velpatasvir (Epclusa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Velpatasvir</intervention_name>
    <description>fixed dose combination medication for the treatment of hepatitis C</description>
    <arm_group_label>Sofosbuvir/Velpatasvir (Epclusa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion/Exclusion Criteria:

        Inclusion Criteria:

          -  Adult age &gt;18 years able to provide consent

          -  Lack of available living donor

          -  Calculated pre-transplant reactive panel (cPRA) of &lt;80%

          -  Estimated post-transplant survival (EPTS) index &gt;20% and &lt;80%

          -  Negative pre-transplant HIV, HCV, and HBV serology and blood HCV PCR

          -  No clinically significant pre-transplant liver disease

          -  Pre-enrollment approval by patient's insurance to cover DAAs therapy

          -  Contraception based on the REMS protocol

          -  Agree to abstinence form alcohol for at least 6 months post-transplant

        Exclusion Criteria:

          -  Living donor available Dialysis time &gt;5 years History of previous organ
             transplantation Listing for multi-organ transplantation Active or recent history (&lt;6
             months) of alcohol or substance abuse Clinically significant liver disease as
             determined by principal investigator History of hepatocarcinoma Pregnancy or lactation
             Refusal to accept blood transfusion HIV infection HCV pcr or antibody positive HBV
             infection

        Donor Inclusion Criteria:

          -  Positive HCV PCR at time of donation

          -  KDPI&lt;85%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reem Daloul, MD</last_name>
    <phone>614-293-4665</phone>
    <email>Reem.Daloul@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Wuebker</last_name>
    <email>Margaret.Wuebker@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Wuebker</last_name>
      <phone>614-293-4665</phone>
      <email>Margaret.Wuebker@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Corey Newsome</last_name>
      <email>Corey.Newsome@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Reem Daloul</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Pesavento</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Michaels</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amer Rajab</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashraf El-Hinnawi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Washburn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.usrds.org/2017/view/Default.aspx</url>
    <description>USRDS Annual Data Report 2017</description>
  </link>
  <reference>
    <citation>Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, Wainright JL, Haynes CR, Snyder JJ, Kasiske BL, Israni AK. OPTN/SRTR 2016 Annual Data Report: Kidney. Am J Transplant. 2018 Jan;18 Suppl 1:18-113. doi: 10.1111/ajt.14557.</citation>
    <PMID>29292608</PMID>
  </reference>
  <reference>
    <citation>Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16.</citation>
    <PMID>26569658</PMID>
  </reference>
  <reference>
    <citation>Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.</citation>
    <PMID>26571066</PMID>
  </reference>
  <reference>
    <citation>Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016 Feb;64(2):301-307. doi: 10.1016/j.jhep.2015.10.005. Epub 2015 Oct 22.</citation>
    <PMID>26476290</PMID>
  </reference>
  <reference>
    <citation>Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.</citation>
    <PMID>26575258</PMID>
  </reference>
  <reference>
    <citation>Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 Oct 15;63(8):1042-1048. doi: 10.1093/cid/ciw496. Epub 2016 Jul 20.</citation>
    <PMID>27444413</PMID>
  </reference>
  <reference>
    <citation>Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol. 2018 Sep;69(3):603-607. doi: 10.1016/j.jhep.2018.05.039. Epub 2018 Jun 8.</citation>
    <PMID>29886154</PMID>
  </reference>
  <reference>
    <citation>Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25.</citation>
    <PMID>29672891</PMID>
  </reference>
  <reference>
    <citation>Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med. 2018 Apr 17;168(8):533-540. doi: 10.7326/M17-2871. Epub 2018 Mar 6.</citation>
    <PMID>29507971</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Reem Daloul</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine, Transplant Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

